Canis ISSN: 2398-2942

Miltefosine

Synonym(s): Milteforan®

Contributor(s): Linda Horspool, Vetstream Ltd

Introduction

Name

  • Miltefosine.

Class of drug

  • Alkylphosphocholine.
  • Membrane-active synthetic ether-lipid analogue.

Description

Chemical name

  • 1-hexadecylphosphorylcholine; 2-(hexadecoxy-oxido-phosphoryl)oxyethyl-trimethyl-azanium or 1-O-hexadecylphosphocholine.

Molecular formula

  • C21H46NO4P

Molecular weight

  • 407.568

Physical properties

  • Crystalline solid.

Storage requirements

  • Solid: for long term storage, store at -20°C. Should be stable for at least 1 year.
  • Solution: should be stored between 15 and 25 °C.
  • Use within one month of first opening.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Control of canine leishmaniosis Canine leishmaniosis.
  • Clinical signs start to improve shortly after treatment is started and continue to improve for up to at least 4 weeks after the end of treatment.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmacokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

  • None known.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references from PubMed and VetMed Resource.
  • Bianciardi P, Brovida C, Valente M, Aresu L, Cavicchioli L, Vischer C, Giroud L, Castagnaro M (2009) Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneys. Toxicol Pathol 37(6), 770-775 PubMed.
  • Manna L, Vitale F, Reale S, Picillo E, Neglia G, Vescio F, Gravino A E (2009) Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis. Vet J 182(3), 441-445 PubMed.
  • Mateo M, Maynard L, Vischer C, Bianciardi P, Miro G (2009) Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis .Parasitol Res 105(1), 155-162 PubMed.
  • Miró G, Oliva G, Cruz I, Cañavate C, Mortarino M, Vischer C, Bianciardi P (2009) Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis. Vet Dermatol 20(5-6), 397-404 PubMed.
  • Woerly V, Maynard L, Sanquer A, Eun H M (2009) Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis. Parasitol Res 105(2), 463-469 PubMed.
  • Manna L, Gravino AE , Picillo E, Decaro N, Buonavoglia C (2008) Leishmania DNA quantification by real-time PCR in naturally infected dogs treated with miltefosine.Ann N Y Acad Sci 1149, 358-360 PubMed.
  • Verma N K, Dey C S (2004) Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob Agents Chemother 48(8), 30103015 PubMed.

Other sources of information

Organisation(s)

  • ESCCAP, The Mews Studio, Portland Road, Malvern, Worcestershire, WR14 2TA. Telephone: ++44 (0)1684 568998 Fax: ++44 (0)5603 102013 E-mail:queries@esccap.org.uk;www.esccap.org.

ADDED